CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lotem, J.
Right arrow Articles by Sachs, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lotem, J.
Right arrow Articles by Sachs, L.

Cell Growth & Differentiation, Vol 5, Issue 3 321-327, Copyright © 1994 by American Association of Cancer Research


ARTICLES

Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways

J Lotem and L Sachs
Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel.

Induction of differentiation in M1 myeloid leukemic cells by the hematopoietic cytokines interleukin 6 and granulocyte-colony stimulating factor, or by the glucocorticoid dexamethasone, was associated with down-regulation of the apoptosis inhibiting gene bcl-2. The cytokine treated leukemic cells showed an increased sensitivity to induction of apoptotic cell death by the cancer chemotherapy compounds Adriamycin and cytosine arabinoside and by heat shock and cycloheximide. Dibutyryl cyclic AMP neither induced differentiation nor down-regulated bcl-2 expression, but it sensitized the cells to induction of apoptosis by some of these agents. Although dexamethasone induced differentiation and down-regulated bcl-2 expression, it did not sensitize the cells to induction of apoptosis and inhibited the apoptosis sensitizing effect of the cytokines and dibutyryl cyclic AMP. Dexamethasone did not inhibit induction of apoptosis by wild-type p53 or viability factor withdrawal. The apoptosis sensitizing effect of the cytokines and dibutyryl cyclic AMP was reversible upon their withdrawal.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
BloodHome page
L. A. Hogarth and A. G. Hall
Increased BAX Expression Is Associated With an Increased Risk of Relapse in Childhood Acute Lymphocytic Leukemia
Blood, April 15, 1999; 93(8): 2671 - 2678.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
L. Garcia-Bermejo, C. Perez, N. E. Vilaboa, E. de Blas, and P. Aller
cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells
J. Cell Sci., March 1, 1998; 111(5): 637 - 644.
[Abstract] [PDF]


Home page
BloodHome page
H. W. Findley, L. Gu, A. M. Yeager, and M. Zhou
Expression and Regulation of Bcl-2, Bcl-xl, and Bax Correlate With p53 Status and Sensitivity to Apoptosis in Childhood Acute Lymphoblastic Leukemia
Blood, April 15, 1997; 89(8): 2986 - 2993.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. A. Hannun
Apoptosis and the Dilemma of Cancer Chemotherapy
Blood, March 15, 1997; 89(6): 1845 - 1853.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1994 by the American Association of Cancer Research.